NDA 050441 · Pfizer
Cleocin Phosphate
Clindamycin Phosphate · Injection
Last checked: Nov 19, 2026Latest source record: Mar 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1972
Oct 2, 1972
Approved uses
1
Original approval plus efficacy supplements
Registered trials
274
66 Phase 3, 28 recruiting
FAERS reports
3,596
2,284 serious, 270 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING WARNING Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be...
What it is approved for
From the label in effect Oct 27, 2026.
INDICATIONS AND USAGE CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. CLEOCIN PHOSPHATE products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. CLEOCIN PHOSPHATE is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 1972 Original approval
1 products under this application
- CLEOCIN PHOSPHATE · CLINDAMYCIN PHOSPHATE EQ 150MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
University of OxfordAcademic, hospital or other
NCT04093765 · 5,542 participants · Start Nov 1, 2018 · Primary completion Dec 31, 2019
Drug: Antimalarials · For: Plasmodium Falciparum Malaria
Sites: Mae Sot, Thailand
- Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial VaginosisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT00642980 · 3,105 participants · Start Apr 2006 · Primary completion Jun 2011
Drug: Clindamycin; Placebo and 1 more · For: Pregnancy
Sites: Lille, France
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01374581 · 2,117 participants · Start May 2012 · Primary completion Jun 2014
Drug: Artemether/Lumefantrine; Artesunate/Amodiaquine and 1 more · For: Malaria
Sites: Kinshasa, Republic of the Congo; Kiruhura, Uganda
- Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean InfectionPivotal-lookingCompleted
Alan TitaAcademic, hospital or other
NCT01235546 · 2,013 participants · Start May 2011 · Primary completion Dec 2015
Drug: Azithromycin and standard of care; Placebo and standard of care · For: Endometritis; Wound Infection; Abscess and 1 more
Sites: Birmingham, Alabama; New Orleans, Louisiana; Jackson, Mississippi · 9 sites in all
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center TrialPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03283878 · 1,770 participants · Start Oct 24, 2017 · Primary completion Nov 20, 2024
Drug: Cefazolin · For: Arthropathy of Knee; Antibiotic Prophylaxis
Sites: San Francisco, California; Atlanta, Georgia; Towson, Maryland · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective373
- rash259
- drug hypersensitivity231
- off label use228
- diarrhoea192
- nausea190
- fatigue171
- pruritus169
- pain164
- condition aggravated135
- dyspnoea116
- headache114
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 53 |
| 2006 | 59 |
| 2007 | 14 |
| 2008 | 20 |
| 2009 | 43 |
| 2010 | 86 |
| 2011 | 66 |
| 2012 | 99 |
| 2013 | 102 |
| 2014 | 103 |
| 2015 | 125 |
| 2016 | 246 |
| 2017 | 184 |
| 2018 | 237 |
| 2019 | 281 |
| 2020 | 210 |
| 2021 | 194 |
| 2022 | 288 |
| 2023 | 305 |
| 2024 | 287 |
| 2025 | 309 |
| 2026 | 264 |
Recalls
4 FDA enforcement reports for this application.
Mar 15, 2019 · Class III · Terminated
Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point
Mar 15, 2019 · Class III · Terminated
Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point
Mar 15, 2019 · Class III · Terminated
Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point
Jun 4, 2013 · Class II · Terminated
Presence of Particulate Matter: Firm is recalling a small number of vials with very small reflective flakes consistent with delamination of the glass vial.
Shortages
FDA's drug shortage list.
Current · updated Nov 6, 2026
Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26). Other
To Be Discontinued · updated Jun 1, 2026
Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Jun 1, 2026
Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Jun 1, 2026
Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Jun 1, 2026
Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26). Discontinuation of the manufacture of the drug
Current · updated Nov 6, 2026
Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cleocin Phosphate (Clindamycin Phosphate)
2024 spending
$9K
Beneficiaries
80
164 claims
Per beneficiary
$115
$0.53 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,801 |
| 2021 | $8,274 |
| 2022 | $3,360 |
| 2023 | $715 |
| 2024 | $9,204 |
Part B: Cleocin Phosphate* (Clindamycin Phosphate*) · HCPCS J0736
2024 spending
$69K
Beneficiaries
11,748
12,338 claims
Per beneficiary
$6
2024 ASP limit $2.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $981 |
| 2024 | $68,958 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antibiotic regimens for postpartum endometritis.
Mackeen AD, Packard RE, Ota E, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
Parks T, Wilson C, Curtis N, et al. · Clin Infect Dis 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis.
Bartoszko JJ, Elias Z, Rudziak P, et al. · BMJ Open 2022 · Meta-Analysis, Systematic Review
- Efficacy of topical treatments for mild-to-moderate acne: A systematic review and meta-analysis of randomized control trials.
Kakpovbia EE, Young T, Milam EC, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review, Network Meta-Analysis
- CABTREOTM (Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide) Topical Gel.
Gupta AK, Mann A, Vincent K, et al. · Skinmed 2024 · Randomized Controlled Trial
- Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.
Liu H, Yu H, Xia J, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.